Key facts
- It has raised $13.7M; the latest was Later Stage VC ($13.7M) in May 2025.
- Notable investors include Guangzhou Science and Technology Financial Innovation Investment Holding, Wanlian Securities Co., Zhangjiagang Jincheng Investment.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Regenverse Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Regenverse Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Regenverse Therapeutics
Provider of regenerative biotechnology solutions intended for clinical therapy, drug development, and personalized medicine. The company offers pluripotent stem cell (iPSC) technology, gene editing, customized cell differentiation, and advanced cell preparation systems, enabling biomedical research institutions and healthcare providers to conduct precise disease modeling, accelerate therapeutic innovation, and implement tailored treatment strategies through scalable and clinically translatable regenerative tools.
- Sector
- Healthcare
- HQ
- Guangzhou, China
- Founded
- 2019
- Employees
- 12
- Website
- gz-regen.com/
- Ownership
- Privately Held (backing)
Regenverse Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Regenverse Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Regenverse Therapeutics in its N-PORT filings yet. We sweep new filings monthly.